{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:18:08Z","timestamp":1790396288661,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T00:00:00Z","timestamp":1535846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"MD Anderson Cancer Center B Cell Lymphoma Moon Shot Program","award":["R21 CA202104"],"award-info":[{"award-number":["R21 CA202104"]}]},{"name":"Gary Rogers Foundation"},{"name":"Fox Family Foundation"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Long term outcomes and mutations in patients with mantle cell lymphoma (MCL) who discontinued ibrutinib have not been described. Using deep targeted next generation sequencing, we performed somatic mutation profiling from 15 MCL patients (including 5 patients with paired samples; before and after progression on ibrutinib). We identified 80 patients with MCL who discontinued ibrutinib therapy for various reasons. Median follow\u2010up after ibrutinib discontinuation was 38\u00a0months. The median duration on ibrutinib was 7\u00b76\u00a0months. Forty\u2010one (51%) patients discontinued ibrutinib due to disease progression\/transformation, 20 (25%) for intolerance, 7 (9%) due to patient choice, 5 (6%) for stem cell transplant, 4 (5%) due to second cancers and 3 (4%) other causes. The median survival after ibrutinib was 10 and 6\u00a0months for disease progression and transformation, respectively, and 25\u00a0months for patients with ibrutinib intolerance. Overall,\n                    <jats:italic>BTK<\/jats:italic>\n                    mutations were observed in 17% patients after progression on ibrutinib. Notably,\n                    <jats:italic>TP53<\/jats:italic>\n                    alterations were observed after progression in 75% patients. Among the 4 patients with blastoid transformation, 3 (75%) had\n                    <jats:italic>NSD2<\/jats:italic>\n                    mutations (co\u2010existing with\n                    <jats:italic>TP53<\/jats:italic>\n                    ). Ibrutinib\u2010refractory MCL patients had a short survival. Demonstration of\n                    <jats:italic>TP53<\/jats:italic>\n                    and\n                    <jats:italic>NSD2<\/jats:italic>\n                    mutations in patients who developed blastoid transformation and\n                    <jats:italic>ATM<\/jats:italic>\n                    and\n                    <jats:italic>TP53<\/jats:italic>\n                    mutations in patients who progressed, opens the door for future investigations in ibrutinib\u2010refractory MCL.\n                  <\/jats:p>","DOI":"10.1111\/bjh.15567","type":"journal-article","created":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T22:48:32Z","timestamp":1535928512000},"page":"578-587","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Long\u2010term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib"],"prefix":"10.1111","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-168X","authenticated-orcid":false,"given":"Preetesh","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma the University of Texas MD Anderson Cancer Center Houston TX USA"},{"name":"Division of Cancer Medicine the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kanagal\u2010Shamanna","sequence":"additional","affiliation":[{"name":"Department of Hematopathology the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makhdum","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Leukemia the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Ghorab","sequence":"additional","affiliation":[{"name":"Department of Leukemia the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Young","family":"Ok","sequence":"additional","affiliation":[{"name":"Department of Hematopathology the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematopathology the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiejun","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Badillo","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystle","family":"Nomie","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard J.","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Department of Hematopathology the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Fowler","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4830-9173","authenticated-orcid":false,"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Champlin","sequence":"additional","affiliation":[{"name":"Department of Stem cell transplant the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma the University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,2]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-719294"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-797019"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf042"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1314608110"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11589"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv111"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0098"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-628792"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779736"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15108"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1517\/21678707.2014.893190"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-603670"},{"key":"e_1_2_9_15_1","article-title":"Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors","author":"Jain P.","year":"2017","journal-title":"British Journal of Haematology"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016004176"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30909-9"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02329-y"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-298349"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-478834"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.204"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3435"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-681460"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.11.4.19154"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-693598"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.2282"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9500"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-517177"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14920"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15567","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T21:55:08Z","timestamp":1694728508000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,2]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1111\/bjh.15567"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15567","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,2]]},"assertion":[{"value":"2018-05-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}